metronidazole has been researched along with Hepatitis C in 2 studies
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.
metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.
Hepatitis C: INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metronidazole was administered intravenously in healthy volunteers, asymptomatic anti-HCV-positive blood donors, and in chronic hepatitis C patients." | 3.70 | Plasma hydroxy metronidazole/metronidazole ratio in anti-HCV carriers with and without apparent liver disease. ( da Silva, CM; David, FL; de Nucci, G; Ferraz, JG; Muscará, MN; Pedrazzoli, J; Polimeno, NC; Sousa, SS, 1998) |
| "A 34-year-old Hispanic man with cirrhosis and hepatitis C being treated with metronidazole for Bacteroides fragilis meningitis and bacteremia developed ataxia, disorientation, and peripheral neuropathy." | 3.70 | Toxic metronidazole-induced MRI changes. ( Horlen, CK; Malouf, CS; Seifert, CF, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| da Silva, CM | 1 |
| David, FL | 1 |
| Muscará, MN | 1 |
| Sousa, SS | 1 |
| Ferraz, JG | 1 |
| de Nucci, G | 1 |
| Polimeno, NC | 1 |
| Pedrazzoli, J | 1 |
| Horlen, CK | 1 |
| Seifert, CF | 1 |
| Malouf, CS | 1 |
2 other studies available for metronidazole and Hepatitis C
| Article | Year |
|---|---|
Plasma hydroxy metronidazole/metronidazole ratio in anti-HCV carriers with and without apparent liver disease.
Topics: Adult; Female; Hepacivirus; Hepatitis C; Humans; Liver; Liver Function Tests; Male; Metronidazole; M | 1998 |
Toxic metronidazole-induced MRI changes.
Topics: Adult; Anti-Infective Agents; Brain; Hepatitis C; Humans; Liver Cirrhosis; Magnetic Resonance Imagin | 2000 |